Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
Authors
Keywords
-
Journal
CLINICAL DRUG INVESTIGATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-27
DOI
10.1007/s40261-019-00820-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
- (2019) Weiting Liao et al. JOURNAL OF MEDICAL ECONOMICS
- First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma
- (2019) XiaoMin Wan et al. JAMA Oncology
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
- (2019) Bernard Escudier NEW ENGLAND JOURNAL OF MEDICINE
- Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Jiasian Teh et al. EUROPEAN UROLOGY
- Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis
- (2019) Seye Abogunrin et al. Future Oncology
- Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
- (2018) Thomas Powles et al. EUROPEAN UROLOGY
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- (2018) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China
- (2018) Guohai Shi et al. JOURNAL OF MEDICAL ECONOMICS
- Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
- (2018) M Gross-Goupil et al. ANNALS OF ONCOLOGY
- Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
- (2018) Bin Wu et al. Journal for ImmunoTherapy of Cancer
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
- (2015) S. Bracarda et al. ANNALS OF ONCOLOGY
- A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study
- (2015) Xiaomin Wan et al. PLoS One
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Current and future systemic treatments for renal cell carcinoma
- (2012) Rosalie Fisher et al. SEMINARS IN CANCER BIOLOGY
- Improved curve fits to summary survival data: application to economic evaluation of health technologies
- (2011) Martin W Hoyle et al. BMC Medical Research Methodology
- Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma
- (2009) Martin Hoyle et al. VALUE IN HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More